Emerging antibody-drug conjugates for treating lymphoid malignancies
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging antibody-drug conjugates for treating lymphoid malignancies
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 22, Issue 3, Pages 259-273
Publisher
Informa UK Limited
Online
2017-08-10
DOI
10.1080/14728214.2017.1366447
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
- (2017) Enrica Marchi et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- 2016 WHO Classification update-What's new in lymphoid neoplasms
- (2017) E. D. Hsi International Journal of Laboratory Hematology
- Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
- (2017) Kurt Schönfeld et al. Journal of Hematology & Oncology
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Treatment approaches of hard-to-treat non-Hodgkin lymphomas
- (2017) Lakshminarayanan Nandagopal et al. Expert Review of Hematology
- Genetic Landscape and Classification of Peripheral T Cell Lymphomas
- (2017) Rosalind F. Sandell et al. Current Oncology Reports
- Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management
- (2016) Stephen M. Ansell AMERICAN JOURNAL OF HEMATOLOGY
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
- (2016) Lydia Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
- (2016) Andre Goy et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
- (2016) Bertrand Coiffier et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2016) Ranjana H. Advani et al. CLINICAL CANCER RESEARCH
- Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
- (2016) M. Ogura et al. CLINICAL CANCER RESEARCH
- Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
- (2016) Daniel W. Sherbenou et al. JOURNAL OF CLINICAL INVESTIGATION
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
- (2016) Nosha Farhadfar et al. LEUKEMIA RESEARCH
- ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
- (2016) M. J. Flynn et al. MOLECULAR CANCER THERAPEUTICS
- The missing link
- (2016) Tiago Rodrigues et al. Nature Chemistry
- Erratum: Corrigendum: Recent advances in the construction of antibody–drug conjugates
- (2016) Vijay Chudasama et al. Nature Chemistry
- Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia
- (2016) Tadeusz Robak et al. SEMINARS IN ONCOLOGY
- New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma
- (2016) Michele Merli et al. Expert Review of Hematology
- New targeted therapies for malignant lymphoma based on molecular heterogeneity
- (2016) Heike Horn et al. Expert Review of Hematology
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
- (2015) E. D. Jacobsen et al. BLOOD
- The development of potential antibody-based therapies for myeloma
- (2015) Daniel W. Sherbenou et al. BLOOD REVIEWS
- Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity
- (2015) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
- (2015) S.-F. Yu et al. CLINICAL CANCER RESEARCH
- Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature
- (2015) P.L. Zinzani et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Potential breakthroughs with investigational drugs for hairy cell leukemia
- (2015) Tadeusz Robak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
- (2015) A. E. Frankel et al. HAEMATOLOGICA
- Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
- (2015) Youn H. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase II Trial of Brentuximab Vedotin for CD30+Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
- (2015) Madeleine Duvic et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
- (2015) M Pfeifer et al. LEUKEMIA
- A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
- (2015) Nina D. Wagner-Johnston et al. LEUKEMIA & LYMPHOMA
- AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
- (2015) D. S. Pereira et al. MOLECULAR CANCER THERAPEUTICS
- Development and Integration of Antibody–Drug Conjugate in Non-Hodgkin Lymphoma
- (2015) Amitkumar Mehta et al. Current Oncology Reports
- Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
- (2015) A. E. Frankel et al. HAEMATOLOGICA
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Anti-CD37 antibodies for chronic lymphocytic leukemia
- (2014) Tadeusz Robak et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies
- (2014) Tadeusz Robak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma
- (2014) Jesus Berdeja Frontiers in Bioscience-Landmark
- Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
- (2014) Michelle A. Fanale et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) P. Moreau et al. ANNALS OF ONCOLOGY
- Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
- (2013) Jonathan L. Kaufman et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2013) V. Ribrag et al. CLINICAL CANCER RESEARCH
- Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance
- (2013) Steve A Maxwell et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
- (2013) Luis Fayad et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
- (2013) Vivien Mak et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
- (2013) D. Li et al. MOLECULAR CANCER THERAPEUTICS
- Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
- (2012) Michinori Ogura et al. CANCER SCIENCE
- Brentuximab vedotin in Hodgkin's lymphoma
- (2012) Barbara Pro et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia
- (2012) Tadeusz Robak Future Oncology
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
- (2012) Kenneth C. Anderson JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
- (2012) K. Elkins et al. MOLECULAR CANCER THERAPEUTICS
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD30 in Anaplastic Large Cell Lymphoma
- (2012) Joseph Vadakara et al. Current Hematologic Malignancy Reports
- I. Epidemiology of adult non-Hodgkin lymphoma
- (2011) P. Boffetta ANNALS OF ONCOLOGY
- A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
- (2011) K.-H. Heider et al. BLOOD
- Peripheral T-cell lymphoma
- (2011) F. M. Foss et al. BLOOD
- A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia
- (2011) John Schindler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
- (2011) D. J. FitzGerald et al. CANCER RESEARCH
- SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
- (2011) V. Blanc et al. CLINICAL CANCER RESEARCH
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Treatment of multiple myeloma
- (2011) S. Vincent Rajkumar Nature Reviews Clinical Oncology
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- (2010) Michinori Ogura et al. CANCER SCIENCE
- Inotuzumab ozogamicin as novel therapy in lymphomas
- (2010) Bryan Y Wong et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-maytansinoid conjugates for the treatment of myeloma
- (2010) Robert J. Lutz et al. mAbs
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
- (2010) M. Lopus et al. MOLECULAR CANCER THERAPEUTICS
- Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma
- (2009) A. Frankel et al. CURRENT DRUG TARGETS
- Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy
- (2008) Kenji Ishitsuka et al. BRITISH JOURNAL OF HAEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search